Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 1:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 5,300 matching trials from the live ClinicalTrials.gov search.
Filters: Louisville, Kentucky Clear all
Not listed Not applicable Interventional

Study Investigating the Ability of Plant Exosomes to Deliver Curcumin to Normal and Colon Cancer Tissue

NCT01294072
View directory record Official record
Conditions
Colon Cancer
Interventions
curcumin, Curcumin conjugated with plant exosomes, No intervention
Dietary Supplement · Other
Lead sponsor
University of Louisville
Other
Eligibility
20 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Oct 18, 2026, 1:16 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers

NCT00626327
View directory record Official record
Conditions
Meningococcal Infections
Interventions
MenACWY-CRM + MMRV, MMRV, MenACWY-CRM
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
7 Months to 1 Year
Enrollment
1,630 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
90
States / cities
Birmingham, Alabama • Dothan, Alabama • Greenville, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2013 · Synced Oct 18, 2026, 1:16 AM EDT
Completed Phase 2 Interventional Results available

Treatment of Moderate to Severe Facial Acne Vulgaris

NCT00612573
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Doxycycline 0.6 mg/kg/day, Doxycycline 1.2 mg/kg/day, Doxycycline 2.4 mg/kg/day, Placebo
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
12 Years to 45 Years
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
23
States / cities
Encino, California • Fremont, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Oct 18, 2026, 1:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Using Media to Shift Social Norms of Violence Among Youth

NCT02706145
View directory record Official record
Conditions
Violence
Interventions
Social norming campaign
Other
Lead sponsor
University of Louisville
Other
Eligibility
10 Years to 24 Years
Enrollment
8,037 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
2
States / cities
Louisville, Kentucky • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Oct 18, 2026, 1:16 AM EDT
Completed Phase 4 Interventional Results available

Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations

NCT02260388
View directory record Official record
Conditions
Cryptogenic Sensory Polyneuropathy
Interventions
Nortriptyline, Duloxetine, Pregabalin, Mexiletine
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
30 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
45
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2018 · Synced Oct 18, 2026, 1:16 AM EDT
Completed Phase 4 Interventional

NICU Antibiotics and Outcomes Trial

NCT03997266
View directory record Official record
Conditions
Microbial Colonization, Extreme Prematurity, Early-Onset Neonatal Sepsis, Late-Onset Neonatal Sepsis, Necrotizing Enterocolitis of Newborn, Death; Neonatal
Interventions
Ampicillin, Gentamycin, Normal saline
Drug
Lead sponsor
Michael Morowitz
Other
Eligibility
Up to 4 Hours
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
14
States / cities
Mobile, Alabama • San Diego, California • New Haven, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 18, 2026, 1:16 AM EDT
Completed Phase 2 Interventional Results available

Study Comparing the Safety and Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure

NCT01731002
View directory record Official record
Conditions
Ocular Hypertension, Open Angle Glaucoma
Interventions
AR-13324 Ophthalmic Solution 0.01%, AR-13324 Ophthalmic Solution 0.02%, Latanoprost ophthalmic solution 0.005%
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
22
States / cities
Artesia, California • Inglewood, California • Newport Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 18, 2026, 1:16 AM EDT
Completed Phase 1 Interventional Results available

Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer

NCT03523572
View directory record Official record
Conditions
Breast Cancer, Urothelial Carcinoma
Interventions
Trastuzumab deruxtecan, Nivolumab
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
10
States / cities
Santa Monica, California • New Haven, Connecticut • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Oct 18, 2026, 1:16 AM EDT
Terminated Phase 3 Interventional Results available

Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH

NCT02725372
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Inhaled Nitric Oxide 75 mcg/kg IBW/hr, Placebo
Drug
Lead sponsor
Bellerophon Pulse Technologies
Industry
Eligibility
18 Years to 85 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
37
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 18, 2026, 1:16 AM EDT
Active, not recruiting Phase 3 Interventional

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

NCT04579224
View directory record Official record
Conditions
Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma, Refractory Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, Docetaxel, Eribulin Mesylate, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Paclitaxel, Sacituzumab Govitecan
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
448
States / cities
Kingman, Arizona • Phoenix, Arizona • Fort Smith, Arkansas + 306 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 18, 2026, 1:16 AM EDT
Active, not recruiting Phase 3 Interventional

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)

NCT07218029
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Sotatercept
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
815 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
36
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 18, 2026, 1:16 AM EDT
Completed Phase 3 Interventional Results available

Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults

NCT05014568
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
tapinarof cream, 1%, Vehicle cream
Drug
Lead sponsor
Organon and Co
Industry
Eligibility
2 Years and older
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
60
States / cities
Birmingham, Alabama • Phoenix, Arizona • Bryant, Arkansas + 53 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Oct 18, 2026, 1:16 AM EDT
Active, not recruiting No phase listed Observational

Destination Therapy Post Approval Study

NCT03681210
View directory record Official record
Conditions
Chronic Heart Failure
Interventions
HeartWare Ventricular Assist Device
Device
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
47
States / cities
Little Rock, Arkansas • San Diego, California • San Francisco, California + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 18, 2026, 1:16 AM EDT
Completed Phase 2 Interventional

Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl.

NCT01265888
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis
Interventions
Inhaled Nitric Oxide
Drug
Lead sponsor
Geno LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2016 · Synced Oct 18, 2026, 1:16 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules in Treating Symptomatic Non-Erosive Gastroesophageal Reflux Disease in Adolescents

NCT01642602
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Dexlansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
12 Years to 17 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
35
States / cities
Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Oct 18, 2026, 1:16 AM EDT
Completed Phase 3 Interventional Results available

A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS)

NCT03571256
View directory record Official record
Conditions
Tourette Syndrome
Interventions
TEV-50717, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
6 Years to 16 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
19
States / cities
Gainesville, Florida • Gulf Breeze, Florida • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 18, 2026, 1:16 AM EDT
Completed Phase 3 Interventional

A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye

NCT02634853
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
1% Tavilermide Ophthalmic Solution, Placebo Ophthalmic Solution
Drug
Lead sponsor
Mimetogen Pharmaceuticals USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
429 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Louisville, Kentucky • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 16, 2019 · Synced Oct 18, 2026, 1:16 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Pregabalin as Add-On Therapy for Partial Onset Seizures in Children Ages 4-16 Years

NCT01389596
View directory record Official record
Conditions
Epilepsy, Partial Seizures
Interventions
Pregabalin add-on therapy
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
4 Years to 16 Years
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
20
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Oct 18, 2026, 1:16 AM EDT
Completed Phase 3 Interventional

Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis

NCT00091351
View directory record Official record
Conditions
Sarcoma
Interventions
conventional surgery, radiation therapy
Procedure · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
55
States / cities
Little Rock, Arkansas • Duarte, California • Aurora, Colorado + 42 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Oct 18, 2026, 1:16 AM EDT
Active, not recruiting Phase 2 Interventional

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

NCT06225596
View directory record Official record
Conditions
Metastatic Urothelial Cancer
Interventions
Zelenectide pevedotin, Pembrolizumab, Gemcitabine + cisplatin Or carboplatin, Avelumab
Drug
Lead sponsor
BicycleTx Limited
Industry
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
13
States / cities
Denver, Colorado • Miami, Florida • Miami Beach, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 18, 2026, 1:16 AM EDT
Recruiting Not applicable Interventional

The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)

NCT05427370
View directory record Official record
Conditions
Coronary Artery Disease, Heart Failure Systolic
Interventions
Revascularization by PCI, Revascularization by CABG
Procedure
Lead sponsor
Sunnybrook Health Sciences Centre
Other
Eligibility
18 Years and older
Enrollment
754 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
6
States / cities
Los Angeles, California • New Haven, Connecticut • Louisville, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 18, 2026, 1:16 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain

NCT02793817
View directory record Official record
Conditions
Post Surgical Ocular Inflammation and Pain
Interventions
KPI-121 1% Ophthalmic Suspension dosed BID, Vehicle of KPI-121 Ophthalmic Suspension dosed BID
Drug
Lead sponsor
Kala Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
35
States / cities
Chandler, Arizona • Phoenix, Arizona • Artesia, California + 32 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Oct 18, 2026, 1:16 AM EDT
Terminated Phase 2 Interventional Results available

A Dose Confirmation and Pharmacokinetic Study of Pegcrisantaspase Administered as Intravenous (IV) Infusion in Children and Young Adults With Acute Lymphoblastic Leukemia (ALL) /Lymphoblastic Lymphoma (LBL). Following Hypersensitivity to Pegaspargase (Oncaspar)

NCT02257684
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Interventions
pegcrisantaspase
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Year to 21 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
43
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 40 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 18, 2026, 1:16 AM EDT
Completed Phase 2 Interventional

The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease

NCT05759208
View directory record Official record
Conditions
Dry Eye Disease
Interventions
OK-101, Placebo
Drug
Lead sponsor
Okyo Pharma Ltd
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
6
States / cities
Newport Beach, California • Colorado Springs, Colorado • Louisville, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2024 · Synced Oct 18, 2026, 1:16 AM EDT